Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Bullboard Posts
Comment by Royal10on Nov 29, 2019 4:38pm
96 Views
Post# 30407095

RE:RE:RE:Insiders

RE:RE:RE:InsidersAbout Gilles Gagnon Prior to forming his pharmaceutical consultancy firm, Prodev Pharma Inc., Gilles Gagnon held several senior executive positions: President and COO, then CEO at AEterna Zentaris; VP External Affairs at Novartis Pharmaceuticals; Executive Director, Corporate Planning and Administration at Sandoz Canada, Inc., to name a few. Throughout his career, in addition to general management functions, he has been particularly involved in corporate development, alliance management, as well as marketing functions. In this capacity he participated in the launch of nine innovative pharmaceutical products. He has also participated in several international committees and strategic advisory boards, holds post-graduate degrees in pharmacology (M.Sc.) and administration (M.B.A) from the Universit1/2 de Sherbrooke, as well as a certificate in General Management from the London Business School
Bullboard Posts